颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效

高璐滢; 林岩松; 姜玉新; 李建初; 刘如玉; 席雪华; 赵瑞娜

doi:10.19401/j.cnki.1007-3639.2019.06.003

您当前的位置：

首页 >

文章列表页 >

颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效

专家述评与论著 | 更新时间：2026-01-27

- 颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效
- Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer
- 中国癌症杂志 2019年29卷第6期页码：418-422
- 作者机构：
  
  1. 中国医学科学院北京协和医学院北京协和医院超声医学科,北京,100730
  2. 中国医学科学院北京协和医学院北京协和医院核医学科,北京,100730
- 作者简介：
- 基金信息：
  
  国家自然科学基金（81571714;81771875）。
- DOI：10.19401/j.cnki.1007-3639.2019.06.003
  中图分类号： R736.1;R445.1;R730.43
- 网络出版：2019-07-12，
  
  纸质出版：2019-07-12
- 稿件说明：
移动端阅览
高璐滢，林岩松，姜玉新，李建初，李慧，张波，刘如玉，席雪华，高琼，王莹，赵瑞娜. 颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效[J]. 中国癌症杂志, 2019, 29(6): 418-422.

高璐滢, 林岩松, 姜玉新, et al. Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer[J]. China Oncology, 2019, 29(6): 418-422.
高璐滢，林岩松，姜玉新，李建初，李慧，张波，刘如玉，席雪华，高琼，王莹，赵瑞娜. 颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效[J]. 中国癌症杂志, 2019, 29(6): 418-422. DOI： 10.19401/j.cnki.1007-3639.2019.06.003.

高璐滢, 林岩松, 姜玉新, et al. Evaluation of short-term efficacy of apatinib using cervical ultrasound and thyroglobulin in the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer[J]. China Oncology, 2019, 29(6): 418-422. DOI： 10.19401/j.cnki.1007-3639.2019.06.003.

摘要

背景与目的：放射性碘难治性分化型甲状腺癌患者（radioactive iodine-refractory differentiated thyroid cancer，RAIR-DTC）的治疗方案有限。结合甲状腺癌血清标志物甲状腺球蛋白（thyroglobulin，Tg），评估阿帕替尼对RAIR-DTC颈部淋巴结转移的治疗效果。方法：2016年1月—2017年12月前瞻性纳入9例成人RAIR-DTC患者，口服阿帕替尼（750mg，每天1次）。持续给药直至病情进展或不能耐受药物引起的不良事件。超声定期监测颈部可疑转移淋巴结的变化，并每2周观察血清Tg的水平变化。结果：该研究9例患者中，男性5例，女性4例，平均年龄52.6（33.0~65.0）岁。颈部可疑淋巴结的最大者的最大径基线均值为29.1 mm，经阿帕替尼治疗8~12周后最大径均值为20.0 mm，平均同比下降31.3%。8例Tg可评价的患者中，全部（100%）经阿帕替尼治疗后Tg水平下降，较基线平均同比下降96.3%。结论：从超声检测颈部转移淋巴结及血清学Tg的变化，证实阿帕替尼可用于RAIR-DTC的治疗。

Abstract

Background and purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a big challenge in the treatment of thyroid cancer. This study aimed to evaluate the therapeutic effect of apatinib mesylate in the treatment of RAIRDTC cervical lymph node metastasis combined with thyroglobulin (Tg)

a serum marker of thyroid cancer. Methods: Nine patients who were diagnosed as having progressive RAIR-DTC were enrolled in this study from Jan. 2016 to Dec. 2017. Patients received oral apatinib 750 mg once a day. Patients continued to be treated until the disease progressed or they were unable to tolerate adverse events. Cervical ultrasound were performed

and serum Tg levels were measured regularly after apatinib treatment to evaluate the response. Results: Of the 9 patients in this study

5 were males and 4 were females with an average age of 52.6 (33-65) years. The baseline average maximum diameter of the largest metastatic cervical lymph nodes was 29.1 mm

and the average maximum diameter was 20.0 mm after 8 to 12 weeks of apatinib treatment. A mean decline of 31.3% could be observed. Of the 8 patients with evaluable Tg

all (100%) patients had a decrease in Tg levels after treatment with apatinib

which was 96.3% lower than the baseline. Conclusion: Ultrasound detection of metastatic cervical lymph node combined with serum Tg level

confirms that apatinib can be used for the treatment of RAIR-DTC.

关键词

Keywords

references

浏览量

2776

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

《2025版美国甲状腺学会成人甲状腺结节管理指南》及《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：甲状腺结节及分化型甲状腺癌超声、CT、MRI以及消融部分的进展

诊断性¹³¹I全身显像在分化型甲状腺癌¹³¹I治疗决策中的作用

乳腺导管原位癌的影像学表现与分子分型、组织病理学分级及预后相关性的研究进展

可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归

儿童及青少年甲状腺结节分级诊断模型的建立与验证